Read the quarter in context.
A source-linked quarter view: reported numbers, management language, guidance, and the risks that should carry forward.
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Revenue
₹7,083 Cr
verified against source
Revenue YoY
12%
reported change
EBITDA
₹1,872 Cr
latest reported figure
Source
nse xbrl
record provenance
Actual signal trajectory
Where this quarter sits.
Quarter read
What the record says.
Dr. Reddy's delivered a strong Q4 FY24 with revenue of INR 7,083 crore (+12% YoY) and EBITDA of INR 1,872 crore (+15% YoY), driven by robust North America generics growth (+26% YoY to $392M) and market share expansion. PAT surged 36% YoY to INR 1,307 crore, aided by a lower effective tax rate. The company reported all-time high full-year revenue of $3.3B and EBITDA margin of 29.7%. Management guided for sustained double-digit growth in emerging markets and India (ex-divestments), with R&D spend of 8.5%-9% of sales. Key strategic moves include the Nestlé JV for consumer health (contributing post-FY27) and a partnership with Sanofi for vaccines. Risks include price erosion in select US products and forex volatility in emerging markets.
Colored figures show movement against the previous available record.
Guidance to track
- Management expects R&D investment to remain in the 8.5%-9% range, with fluctuations based on clinical trial timing.
- Excluding divestment income, India business is expected to continue double-digit growth, driven by new product launches and partnerships.
- The joint venture with Nestlé will require initial investment and brand registration; meaningful revenue contribution expected after FY27.
- Internal biosimilar pipeline expected to yield first product launch in Europe and US in FY27, with profitability thereafter.
Risks flagged
- Management acknowledged price erosion on select large products, partially offset by other products. Continued erosion could pressure US margins.
- Emerging market growth in constant currency may be offset by unfavorable forex movements, particularly in Russia and other markets.
- US FDA issued a complete response letter for biosimilar Rituximab due to CMC questions; resolution expected around September, but timeline for approval remains uncertain.
- Multiple new entrants in the generic Revlimid market could impact pricing and volume, though management declined to discuss specifics.
Key quotes
- We delivered strong financial results in FY 2024. Our growth and profitability in this year have been driven by our performance in the U.S.
- The overall sentiment is unchanged. Still, the lion's share of the interest, I think, is sustainability of service and supply, and this is still the case.
- We believe that the brands, our brands, that we decided to continue to focus on, will stay for a while, like, Prasad just said.
Research modules